Computational analysis of high-density peptide microarray data with application from systemic sclerosis to multiple sclerosis.

Auto-antibodies are implicated in the pathophysiology of various autoimmune diseases. High-density peptide microarrays incubated with human serum can detect antibody reactivities against thousands of peptides. This enables the identification of new auto-antigens and the determination of the parts of protein antigens (epitopes) that are recognized by antibody paratopes. We discuss the utility of peptide microarrays to investigate epitope-antibody-recognitions (EAR) from systemic sclerosis to multiple sclerosis. The technology can help to establish reliable diagnostic and prognostic biomarkers employing a combination of antigenic peptides. We describe the specifics of peptide microarray data and present bioinformatic methods for their analysis. Quality control, data pre-processing and the filtering of specific peptides are demonstrated on an example data set. Peptide microarrays representing 24 selected proteins by 3235 overlapping 15mer peptides were used to measure antibodies in serum of 10 patients with limited cutaneous systemic sclerosis (SSC) and 10 healthy blood donors. The data showed a sparse and skewed distribution, and we observed strong individual differences since many peptide sequences were bound by antibodies of only one serum sample. In the sera of the SSc patients, but not of the healthy controls, we found antibodies to three peptides MGPRRRSRKPEAPRR, TPTPGPSRRGPSLGA and GPSRRGPSLGASSHQ that share a similar sequence motif (GP-R/S-RR). These peptides map to two known linear epitopes at the N-terminus of centromere protein A (CENPA), demonstrating the utility of peptide microarrays. Presented experimental and bioinformatic approach can be applied in the same manner for multiple sclerosis research.

[1]  S. Cook,et al.  Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis , 2003, Journal of Neuroimmunology.

[2]  U. Zettl,et al.  Autoantibodies in autoimmune diseases. , 2010, Current pharmaceutical design.

[3]  Michael Mahler,et al.  Epitope specificity and significance in systemic autoimmune diseases , 2010, Annals of the New York Academy of Sciences.

[4]  A. Compston,et al.  Multiple sclerosis. , 2002, Lancet.

[5]  Marina Cretich,et al.  Protein and peptide arrays: recent trends and new directions. , 2006, Biomolecular engineering.

[6]  W. Robinson,et al.  Epitope spreading to citrullinated antigens in mouse models of autoimmune arthritis and demyelination , 2008, Arthritis research & therapy.

[7]  Lawrence Steinman,et al.  Microarray Profiling of Antibody Responses against Simian-Human Immunodeficiency Virus: Postchallenge Convergence of Reactivities Independent of Host Histocompatibility Type and Vaccine Regimen , 2003, Journal of Virology.

[8]  M. Mahler,et al.  Fine-specificity of the anti-CENP-A B-cell autoimmune response , 2000, Journal of Molecular Medicine.

[9]  J. Mussini,et al.  [Immunology of multiple sclerosis]. , 1982, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.

[10]  Veerle Somers,et al.  Multiplexing approaches for autoantibody profiling in multiple sclerosis. , 2009, Autoimmunity reviews.

[11]  Ariel Miller,et al.  Serum anti-Glc(α1,4)Glc(α) antibodies as a biomarker for relapsing–remitting multiple sclerosis , 2006, Journal of the Neurological Sciences.

[12]  A. Osterhaus,et al.  No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[13]  A. Verkman,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[14]  G. Ellison,et al.  A humoral response to oligodendrocyte-specific protein in MS , 1999, Neurology.

[15]  G. Guazzi,et al.  Early synthesis and correlation of serum anti-thyroid antibodies with clinical parameters in multiple sclerosis , 1999, Journal of the Neurological Sciences.

[16]  M. Snyder,et al.  Analyzing antibody specificity with whole proteome microarrays , 2003, Nature Biotechnology.

[17]  Bonnie Bruce,et al.  Antigen microarray profiling of autoantibodies in rheumatoid arthritis. , 2005, Arthritis and rheumatism.

[18]  A. Ascherio,et al.  Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults , 2008, Neurology.

[19]  J. Lindstrom,et al.  Antibody to acetylcholine receptor in myasthenia gravis , 1976, Neurology.

[20]  W. Robinson,et al.  Protein and peptide array analysis of autoimmune disease. , 2002, BioTechniques.

[21]  J. Satoh,et al.  Detection of anti‐Nogo receptor autoantibody in the serum of multiple sclerosis and controls , 2007, Acta neurologica Scandinavica.

[22]  S. Izumo,et al.  Significantly increased antibody response to heterogeneous nuclear ribonucleoproteins in cerebrospinal fluid of multiple sclerosis patients but not in patients with human T-lymphotropic virus type I—associated myelopathy/tropical spastic paraparesis , 2011, Journal of NeuroVirology.

[23]  J. Kukal,et al.  Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis , 2007, Journal of Neurology.

[24]  E. Silber,et al.  Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit , 2002, Neurology.

[25]  A. Bartoš,et al.  Cerebrospinal fluid antibodies to tubulin are elevated in the patients with multiple sclerosis , 2008, European journal of neurology.

[26]  H. Lassmann,et al.  Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals , 2009, Proceedings of the National Academy of Sciences.

[27]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[28]  P. Lalive Autoantibodies in inflammatory demyelinating diseases of the central nervous system. , 2008, Swiss medical weekly.

[29]  D. Mattson,et al.  Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis , 1994, The Journal of experimental medicine.

[30]  M. Snyder,et al.  Protein microarray technology , 2006, Mechanisms of Ageing and Development.

[31]  B. E. Black,et al.  The Structure of (CENP-A/H4)2 Reveals Physical Features that Mark Centromeres , 2010, Nature.

[32]  U. Müller-Ladner,et al.  Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database , 2007, Annals of the rheumatic diseases.

[33]  J. Aarseth,et al.  Proteasome Antibodies in Patients with Cancer or Multiple Sclerosis , 2008, Scandinavian journal of immunology.

[34]  Nimrod D. Rubinstein,et al.  Computational characterization of B-cell epitopes. , 2008, Molecular immunology.

[35]  T. Olsson,et al.  Neurofascin as a novel target for autoantibody-mediated axonal injury , 2007, The Journal of experimental medicine.

[36]  M. Kunimatsu,et al.  Autoepitopes on autoantigen centromere protein‐A (CENP‐A) are restricted to the N‐terminal region, which has no homology with histone H3 , 2000, Clinical and experimental immunology.

[37]  Daniel Thomas,et al.  Recognition and Degradation of Myelin Basic Protein Peptides by Serum Autoantibodies: Novel Biomarker for Multiple Sclerosis1 , 2008, The Journal of Immunology.

[38]  D. Arnold,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.

[39]  Reinhard Hohlfeld,et al.  Multiple Sclerosis: A Comprehensive Text , 2008 .

[40]  S. van den Noort,et al.  Triosephosphate Isomerase- and Glyceraldehyde-3-Phosphate Dehydrogenase-Reactive Autoantibodies in the Cerebrospinal Fluid of Patients with Multiple Sclerosis1 , 2006, The Journal of Immunology.

[41]  Lawrence Steinman,et al.  Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis , 2003, Nature Biotechnology.

[42]  Eytan Domany,et al.  Functional immunomics: Microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetes , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Y. Hayashi,et al.  High prevalence of autoantibodies against phosphoglycerate mutase 1 in patients with autoimmune central nervous system diseases , 2010, Journal of Neuroimmunology.

[44]  L. Kappos,et al.  Neutralising antibodies to interferon β during the treatment of multiple sclerosis , 2003, Journal of neurology, neurosurgery, and psychiatry.

[45]  F. Paoletti,et al.  Transketolase and 2′,3′-Cyclic-nucleotide 3′-Phosphodiesterase Type I Isoforms Are Specifically Recognized by IgG Autoantibodies in Multiple Sclerosis Patients *S , 2008, Molecular & Cellular Proteomics.

[46]  T. Holmøy The Discovery of Oligoclonal Bands: A 50-Year Anniversary , 2009, European Neurology.

[47]  F. Dammacco,et al.  The immunodominant epitope of centromere-associated protein A displays homology with the transcription factor forkhead box E3 (FOXE3). , 2010, Clinical immunology.

[48]  Marie Reilly,et al.  Validation of peptide epitope microarray experiments and extraction of quality data. , 2007, Journal of immunological methods.

[49]  Y. Hamaguchi Autoantibody profiles in systemic sclerosis: Predictive value for clinical evaluation and prognosis , 2010, The Journal of dermatology.

[50]  A. Burks,et al.  Microarray immunoassay: association of clinical history, in vitro IgE function, and heterogeneity of allergenic peanut epitopes. , 2004, The Journal of allergy and clinical immunology.

[51]  M. Schwab,et al.  Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders , 2003, Journal of Neuroimmunology.

[52]  R. Herndon,et al.  Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis , 1998, Neurology.

[53]  Jerry Li,et al.  Within the fold: assessing differential expression measures and reproducibility in microarray assays , 2002, Genome Biology.

[54]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[55]  I. Regidor,et al.  Anti-heat shock protein 90β antibodies are detected in patients with multiple sclerosis during remission , 2007, Journal of Neuroimmunology.

[56]  Guillermo Izquierdo,et al.  Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis , 2008, Proceedings of the National Academy of Sciences.

[57]  F. Barkhof,et al.  Week 144 Results of a Phase II, Randomized, Multicenter Trial Assessing the Safety and Efficacy of Ocrelizumab in Patients with Relapsing–Remitting Multiple Sclerosis (RRMS) (S31.004) , 2013 .

[58]  E. Hachulla,et al.  Diagnosis and Classification of Systemic Sclerosis , 2011, Clinical reviews in allergy & immunology.

[59]  M. Schutkowski,et al.  Pattern Recognition in Pulmonary Tuberculosis Defined by High Content Peptide Microarray Chip Analysis Representing 61 Proteins from M. tuberculosis , 2008, PloS one.

[60]  E. Cooper,et al.  Antibodies to myelin basic protein, myelin oligodendrocytes peptides, α‐β‐crystallin, lymphocyte activation and cytokine production in patients with multiple sclerosis , 2003, Journal of internal medicine.

[61]  T. Olsson,et al.  Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls , 1991, European journal of immunology.

[62]  P. Brown,et al.  Autoantigen microarrays for multiplex characterization of autoantibody responses , 2002, Nature Medicine.

[63]  Michael Hecker,et al.  Integrative modeling of transcriptional regulation in response to antirheumatic therapy , 2009, BMC Bioinformatics.

[64]  P. Lorenz,et al.  Probing the epitope signatures of IgG antibodies in human serum from patients with autoimmune disease. , 2009, Methods in molecular biology.

[65]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[66]  T. Olsson,et al.  Multiple Sclerosis: Cells Secreting Antibodies Against Myelin‐Associated Glycoprotein are Present in Cerebrospinal Fluid , 1991, Scandinavian journal of immunology.

[67]  Marie Reilly,et al.  Visualisation and pre-processing of peptide microarray data. , 2009, Methods in molecular biology.

[68]  P. Vermersch,et al.  α-Fodrin autoantibodies in the differential diagnosis of MS and Sjögren syndrome , 2003, Neurology.

[69]  L. Kappos,et al.  Age-Dependent B Cell Autoimmunity to a Myelin Surface Antigen in Pediatric Multiple Sclerosis1 , 2009, The Journal of Immunology.

[70]  S. Yokota,et al.  Autoantibodies against HSP70 family proteins were detected in the cerebrospinal fluid from patients with multiple sclerosis , 2006, Journal of the Neurological Sciences.